Ikerbasque, the Basque Foundation for Science, organized a webinar in which a reflection on the RNA therapies was conducted regarding both their scientific applications and their ethical implications.
The event was moderated by the Scientific Director of Ikerbasque Fernando Cossío, and had the participation of:
- Laura Sepp-Lorenzino is Executive Vice President and Chief Scientific Officer (CSO) at Intellia Therapeutics, a leading developer of CRISPR/Cas9-based therapies for in vivo and ex vivo genome editing. Prior to joining Intellia, Laura was Vice President, Head of Nucleic Acid Therapies and External Innovation Team Member at Vertex Pharmaceuticals, held positions as Vice President and Resident Entrepreneur at Alnylam Pharmaceuticals, Inc., and was Executive Director of RNA Therapies at Merck & Co., Inc. In addition to her extensive experience in nucleic acid therapies, Laura has prior experience in oncology drug development having led the Cancer Research department at Merck West Point and having been an investigator at Memorial Sloan- Kettering Cancer Center.
- Virginia Arechavala Gomeza is an Ikerbasque researcher at the Biocruces Bizkaia Health Research Institute, where she leads the "Nucleic Acid Therapies for Rare Diseases" group. In addition, she leads the international COST DARTER network, which includes more than 400 researchers looking for ways to improve the distribution of new nucleic acid-based medicines (www.antisenserna.eu).
The event was held on April 26 at 17:00 (CET).
.png)
